Navigation Links
New Type of Stent Appears Safe, Effective
Date:9/1/2008

Artery-opening device emits drug from a biodegradable polymer

MONDAY, Sept. 1 (HealthDay News) -- One of a "new generation" of artery-opening, drug-eluting stents appears equally effective as older models in boosting outcomes for heart patients, a new head-to-head study shows.

Stents are tiny mesh tubes inserted into arteries to keep blood flowing. Drug-eluting stents emit medicines that help prevent reclosure. The latest form of drug-eluting stents releases the drugs from a biodegradable polymer coating.

In the new study, published early online Sept. 1 in The Lancet, researchers in Switzerland compared one such stent, which releases the drug biolimus, against a standard drug-eluting stent releasing sirolimus. Adult heart patients with chronic stable coronary artery disease or acute coronary syndromes were randomized to receive either of the two stents. A subset (427 patients) later underwent angiography to see how well the stent was performing.

After nine months of follow-up, researchers led by Professor Stephan Windecker of Bern University Hospital reported that biolimus-eluting stents were as effective as the sirolimus stent in terms of the number of patients who experienced a combination of cardiac death, heart attack or need for a repeat revascularization procedure of the treated vessel -- 9 percent for the biolimus group and 11 percent for those receiving the sirolimus stent.

There were also no significant difference between the biolimus and sirolmus stent groups when each event was looked at separately: cardiac death (1.6 percent vs. 2.5 percent, respectively), heart attack (5.7 percent vs. 4.6 percent) and repeat procedures (4.4 percent vs. 5.5 percent). Each stent also performed similarly in terms of the percentage of vessel diameter that reclosed over the nine-month period, the team noted.

According to the authors, the study, "establishes the non-inferiority" of the newer biolimus-eluting stent.

But in an editorial, Dr. Ron Waksman, of Washington Hospital Center, Washington, D.C., was more cautious. "Before we become overly enthused with new-generation drug-eluting stents, we should call for new-generation trial designs that will enable us to assess whether or not these new stents are necessarily better," he wrote.

The study, which was expected to be presented Monday at the European Society of Cardiology meeting in Munich, was funded by the maker of the biolimus stent, Biosensors Europe SA, Switzerland.

More information

There's more on stents and stenting at the American Heart Association.



-- E.J. Mundell



SOURCE: The Lancet, news release, Sept. 1, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. MD On-Line Achieves CAQH CORE(TM) Certification for Consistent Healthcare Administrative Data Exchange
2. NYC first: Complex aneurysm treated using new fenestrated endograft stent
3. Drug-Coated Stents Reduce Repeat Artery Procedures
4. How to use endoscopic stent for biliary stricture trauma?
5. Abbott Submits Application for Approval of XIENCE(TM) V Everolimus Eluting Coronary Stent System in Japan
6. Edwards Lifesciences Receives Additional Questions From the FDA About the LifeStent Product Line
7. OrbusNeich Receives Approval to Market Genous(TM) Bio-engineered R stent(TM) in Taiwan
8. More patients with drug-coated cardiac stents survive, avoid costly follow-up procedures
9. Study analyzed SYMBICORT in children with persistent asthma
10. High Growth Potential for Carotid Stent and Thoracic Aortic Stent Graft Markets
11. TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients with Diabetes Compared to Non-Diabetics in ARRIVE Registry Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily ... of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures ... . Simply select a ProHand generator and drag it above media or text in ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was ... his family verbally and physically. , “When something upset him, he couldn’t control his emotions,” ... He would throw rocks at my other children and say he was going to kill ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, ... treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including robotic ... osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016 Research and Markets has announced ... Diagnostic Tests" report to their offering. ... The World Market for Companion Diagnostics covers ... Market analysis in the report includes the following: ... Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
(Date:6/24/2016)... , Belgium , June 24, ... VNRX), today announced the appointment of Dr. ... Directors as a Non-Executive Director, effective June 23, ... Audit, Compensation and Nominations and Governance Committees.  As ... Futcher will provide independent expertise and strategic counsel ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... Forecast to 2022" report to their offering. ... the patients with kidney failure, it replaces the function of ... patient,s blood and thus the treatment helps to keep the ... balance. Increasing number of ESRD patients & ...
Breaking Medicine Technology: